Dr. Ryu joined the Department of Dermatology at the Boston University of School of Medicine as an assistant Professor in 2011. He received his Ph.D. degree from Oregon State University in Molecular Toxicology. Dr. Ryu completed his postdoctoral fellowships at the National Cancer Institute in Bethesda, Maryland and Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Ryu served as an assistant member of the Nevada Cancer Institute at Las Vegas, Nevada and clinical assistant professor of medicine at the University of Nevada School of Medicine at Reno, Nevada. Dr. Ryu is a recipient of Howard Temin Award, career development award (K01), from the National Cancer Institute.
Dr. Ryu’s research interest is to determine the molecular events that dictate melanoma tumorigenicity and malignant progression. It is likely that identification of such molecular pathways will allow us to identify clinically useful biomarkers as well as potential therapeutic targets against this lethal form of skin cancer.
Biomarkers for melanoma progression: Dr. Ryu’s laboratory currently focuses on discovery of molecular biomarkers that can be used for patient stratification and personalized therapy. His laboratory uses genomic and molecular profiling techniques on tissue and blood samples from melanoma patients to find patterns of molecular signatures and correlate them with clinical outcomes.
Therapeutic targeting of metastasis-initiating cells (MICs): Despite recent progress, the molecular mechanisms of tumor metastasis remain unclear. Isolation and dissection of the MICs, subpopulation of tumor cells including circulating cancer cells in patient’s blood, will shed light on the molecular events of metastasis progression. Dr. Ryu’s laboratory focuses on the genetic and epigenetic characterization of the MICs as well as developing therapeutic and preventive strategies of cancer metastasis by targeting the MICs.
- Oregon State University, PhD
- Chonbuk National University, MS
- Chonbuk National University, BS
- Published on 2/1/2018
Eisenstein A, Panova IP, Chung HJ, Goldberg LJ, Zhang Q, Lazova R, Bhawan J, Busam KJ, Symanowski JT, Alani RM, Ryu B. Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions. Melanoma Res. 2018 Feb; 28(1):71-75. PMID: 29227334.
- Published on 1/4/2018
Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 Jan 04; 9(1):53. PMID: 29302039.
- Published on 2/6/2017
Hsu MY, Yang MH, Schnegg CI, Hwang S, Ryu B, Alani RM. Notch3 signaling-mediated melanoma-endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis. Lab Invest. 2017 Jun; 97(6):725-736. PMID: 28165469.
- Published on 4/24/2015
Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munshi R, Ryu B. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 2015 Sep; 135(9):2283-91. PMID: 25910030.
- Published on 6/11/2014
Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, Riker AI, Alani RM, Ryu B. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. Br J Dermatol. 2014 Aug; 171(2):403-8. PMID: 24359286.
- Published on 8/22/2013
Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013 Aug 22; 51(4):409-22. PMID: 23973372.
- Published on 5/1/2013
Ryu B, Hwang S, Alani RM. MicroRNAs as an emerging target for melanoma therapy. J Invest Dermatol. 2013 May; 133(5):1137-9. PMID: 23594536.
- Published on 4/18/2013
Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, Dancy BM, Bowers EM, Meyers D, Lareau L, Cole PA, Taverna SD, Alani RM. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol. 2013 Oct; 133(10):2444-52. PMID: 23698071.
- Published on 1/23/2013
Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol. 2013 Aug; 133(8):2041-9. PMID: 23344460.
- Published on 3/31/2011
Ryu B, Moriarty WF, Stine MJ, DeLuca A, Kim DS, Meeker AK, Grills LD, Switzer RA, Eller MS, Alani RM. Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J Invest Dermatol. 2011 Jul; 131(7):1579-83. PMID: 21451543.
View 23 more publications: View full profile at BUMC